Alnylam Pharmaceuticals
Scientist, DMPK
Alnylam Pharmaceuticals, Cambridge, Massachusetts, us, 02140
This role is considered Hybrid.Overview
Join our dynamic research and development team dedicated to advancing oligonucleotide-based therapeutics. We are seeking a highly skilled Ph.D. scientist to focus on the disposition mechanisms and pharmacokinetic/pharmacodynamic (PK/PD) relationships of our drug candidates. As a key member of our DMPK team, you will work collaboratively with colleagues across Research.Key Responsibilities
Develop DMPK Strategies:
Formulate and implement DMPK strategies that align with our platform, program objectives, and overall company goals to support robust discovery pipelines and facilitate successful global drug registration.Collaborate on siRNA Delivery:
Work closely with Research scientists and project leaders to optimize siRNA delivery to target tissues, and aid in drug candidate selection, characterization, and progression into development.Integrate PK/PD Data:
Partner with Research, Toxicology, and Clinical Pharmacology teams to apply model-based approaches for integrating PK/PD and safety data to guide clinical development plans.Represent DMPK:
Actively participate in interdisciplinary teams, representing DMPK expertise and contributing to collaborative projects.Support Regulatory Submissions:
Ensure timely delivery of detailed reports and key sections of regulatory documents to support INDs, NDAs, and other global regulatory submissions.Qualifications
Educational Background:
Ph.D. in Pharmacokinetics, Pharmacology, Biophysics, Bioengineering, or a related field.Expertise:
In-depth knowledge of pharmacokinetics and PK/PD principles.Passion for Discovery:
Demonstrated enthusiasm for disease networks and drug discovery processes.Analytical Skills:
Proficiency in model-based data integration, analysis, and projection.Problem-Solving:
Proven ability to solve complex problems and use modeling and simulation for data integration.Communication:
Excellent interpersonal, written, and verbal communication skills.Experience:
Preferably experienced with oligonucleotide-based therapeutics, molecular biology, and genetics. Alternatively, experience with various drug modalities is also acceptable.About Alnylam:
Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by "interfering" with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.Our culture:
Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we've been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as one of Science Magazine's Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK - among others.At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients.
#J-18808-Ljbffr
Join our dynamic research and development team dedicated to advancing oligonucleotide-based therapeutics. We are seeking a highly skilled Ph.D. scientist to focus on the disposition mechanisms and pharmacokinetic/pharmacodynamic (PK/PD) relationships of our drug candidates. As a key member of our DMPK team, you will work collaboratively with colleagues across Research.Key Responsibilities
Develop DMPK Strategies:
Formulate and implement DMPK strategies that align with our platform, program objectives, and overall company goals to support robust discovery pipelines and facilitate successful global drug registration.Collaborate on siRNA Delivery:
Work closely with Research scientists and project leaders to optimize siRNA delivery to target tissues, and aid in drug candidate selection, characterization, and progression into development.Integrate PK/PD Data:
Partner with Research, Toxicology, and Clinical Pharmacology teams to apply model-based approaches for integrating PK/PD and safety data to guide clinical development plans.Represent DMPK:
Actively participate in interdisciplinary teams, representing DMPK expertise and contributing to collaborative projects.Support Regulatory Submissions:
Ensure timely delivery of detailed reports and key sections of regulatory documents to support INDs, NDAs, and other global regulatory submissions.Qualifications
Educational Background:
Ph.D. in Pharmacokinetics, Pharmacology, Biophysics, Bioengineering, or a related field.Expertise:
In-depth knowledge of pharmacokinetics and PK/PD principles.Passion for Discovery:
Demonstrated enthusiasm for disease networks and drug discovery processes.Analytical Skills:
Proficiency in model-based data integration, analysis, and projection.Problem-Solving:
Proven ability to solve complex problems and use modeling and simulation for data integration.Communication:
Excellent interpersonal, written, and verbal communication skills.Experience:
Preferably experienced with oligonucleotide-based therapeutics, molecular biology, and genetics. Alternatively, experience with various drug modalities is also acceptable.About Alnylam:
Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by "interfering" with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.Our culture:
Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we've been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as one of Science Magazine's Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK - among others.At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients.
#J-18808-Ljbffr